Annie Bargsten has medical school training from Capital Medical University and a PhD in Cell and Molecular Biology from Colorado State University, where she focused on RNA decay in Myotonic Dystrophy. With over 12 years of experience in academia and the biotech industry, she has worked on bench science, including RNA decay and CAR-T cell therapy, as well as in technical support and field application roles. She currently serves as a Field Application Scientist for Primary Cells at STEMCELL Technologies.